CD4 and neoplasm: Deniger et al. (2018) isolated and expanded TILs from nine patients with metastatic ovarian cancer and discovered CD4+ T cell reactivity to tumor-intrinsic mutant p53 in two of them. In subsequent studies, TIL responses to hotspot p53 mutations were evaluated in more than 40 patients with different tumor types, and both CD4+ and CD8+ T cell reactivity was demonstrated in 22 individuals (Kim et al. 2022, Malekzadeh et al. 2019).